Kiadis Pharma N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
01 feb 2016 - 07:05
Statutaire naam
Kiadis Pharma N.V.
Titel
Kiadis Pharma and The Leukemia & Lymphoma Society enter partnership for the development of ATIR101™ in ALL and AML patients
Bericht
Amsterdam, The Netherlands, February 1, 2016 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces that it has entered into a partnership with The Leukemia & Lymphoma Society (LLS) under which LLS will fund the Phase II development of Kiadis Pharma’s lead product, ATIR101™, through an equity investment of approximately $1 million.
Datum laatste update: 23 februari 2026